Trial
NCT03912350
The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Autism Spectrum Disorder
Intervention
Balovaptan
Why stopped
The study is on hold due to stopping of the Autism Spectrum Disorder program with balovatpan, the study drug.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-08